Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study
暂无分享,去创建一个
A. Strafella | C. Tassinari | F. Valzania | C. A Tassinari | A. P Strafella | F Valzania | S. A Nassetti | A Tropeani | A Bisulli | M Santangelo | M. Santangelo | S. Nassetti | A. Bisulli | A. Tropeani | A. P. Strafella | S.A Nassetti | C.A Tassinari
[1] J. Rothwell,et al. Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[2] B. G. Blijenberg,et al. Spectrophotometric analysis of CSF after subarachnoid hemorrhage , 1983, Neurology.
[3] T. Chase,et al. Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies , 1987, Annals of neurology.
[4] J. Bartko,et al. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II , 1988, Annals of neurology.
[5] J. Rothwell,et al. Interaction between intracortical inhibition and facilitation in human motor cortex. , 1996, The Journal of physiology.
[6] A Rothenberger,et al. Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. , 1997, The American journal of psychiatry.
[7] F. Calon,et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex , 1995, Brain Research.
[8] H. Tsuji,et al. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. , 1997, The Journal of physiology.
[9] R. Inzelberg,et al. Changes in excitability of motor cortical circuitry in patients with parkinson's disease , 1995, Annals of neurology.
[10] B. Steinhoff,et al. Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study , 1996, Annals of neurology.
[11] R. Watts. The role of dopamine agonists in early Parkinson's disease , 1997, Neurology.
[12] J. Cedarbaum,et al. Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation , 1990, Movement Disorders.
[13] C. Marsden,et al. Receptor changes during chronic dopaminergic stimulation. , 1988, Journal of neural transmission. Supplementum.
[14] Walter Paulus,et al. Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation , 1996, Neuroscience Letters.
[15] W Paulus,et al. Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. , 1997, Electroencephalography and clinical neurophysiology.
[16] J. Jankovic. Long‐term study of pergolide in Parkinson's disease , 1985, Neurology.
[17] C. Marsden,et al. Corticocortical inhibition in human motor cortex. , 1993, The Journal of physiology.
[18] N Accornero,et al. Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. , 1994, Brain : a journal of neurology.
[19] M Hallett,et al. Effects of phenytoin on cortical excitability in humans , 1997, Neurology.
[20] Ichiro Kanazawa,et al. Ipsilateral cortico-cortical inhibition of the motor cortex in various neurological disorders , 1996, Journal of the Neurological Sciences.